ClinicalTrials.gg
TerminatedNCT03942211SPHINXUpdated May 8, 2024Results posted

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

A Phase 2 interventional study of Selexipag and Placebo in Sarcoidosis-associated Pulmonary Hypertension, sponsored by Actelion. Terminated at 38 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
The sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.

Enrollment
47th of 69
10 · median 16
Started
2021
with 4 others
Phase 2
26 of 115
4 open now
Registered
82nd of 115
by date

Among the 115 studies in Sarcoidosis with a site in United States, this one is the 47th largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2021, is one of 26 in phase 2, and was the 82nd registered.

Sarcoidosis

271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.

Browse Sarcoidosis studies →

Open to participants now

23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Sarcoidosis studies recruiting now, 30 (75%) set no upper age limit and 1 (3%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Sarcoidosis with a site in United States, or all of them as a file.
02

Study summary

Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH). The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).

Read the detailed description

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate several cardiovascular and respiratory diseases. Sarcoidosis is a multisystemic disorder that is characterized by non-caseating granulomas which are present in multiple tissues, particularly in the lung and lymphatic system. Severe untreated pulmonary hypertension (PH) carries a poor prognosis and is associated with higher mortality in participants with interstitial lung diseases and sarcoidosis. While there is no approved treatment for SAPH, PH-specific treatments are frequently used. Selexipag is a selective, orally available and long-acting non-prostanoid agonist of the prostacyclin receptor (prostacyclin [IP] receptor) for the treatment of patients with PAH. The rationale for this study is based on the unmet medical need for new therapeutic options for patients with SAPH and is supported by the established efficacy and safety of selexipag in the PAH indication, the shared pathomechanism between SAPH and PAH, and the available data on the efficacy and safety of PH-specific therapies in SAPH. This study consists of screening period, main observation period and double blind extension period and safety follow-up period. The duration of individual participation in the study will be different for each individual participant (between approximately 15 months and up to approximately 3.5 years) and will depend on the time of each participant's individual date of entering the study and the total recruitment time. The efficacy assessments include right heart catheterization (RHC), assessment of exercise capacity, dyspnea, pulmonary function tests, etc. Safety and tolerability will be evaluated throughout the study and includes review of concomitant medications and adverse events (AEs), clinical laboratory tests, 12-lead electrocardiogram (ECG), vital signs, physical examination, and pregnancy testing.

03

Conditions studied

  • Sarcoidosis-associated Pulmonary Hypertension

Keywords

  • selexipag, sarcoidosis, pulmonary hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Confirmed diagnosis of sarcoidosis as per American Thoracic Society (ATS) criteria
  • Sarcoidosis-associated precapillary PH, confirmed by RHC (at rest) within 90 days prior to randomization.
  • PH severity according to modified WHO FC II-IV at Screening and randomization; participants in WHO FC IV must be in a stable condition and able to perform a 6MWT.
  • Either not receiving treatment with PH-specific treatment or oral PH-specific monotherapy (ie, riociguat or PDE5i or ERA); if on oral PH-specific monotherapy then treatment had to be stable (ie, no introduction of new therapies or changes in dose) for at least 90 days prior to both and the RHC qualifying for enrollment and randomization
  • Stable sarcoidosis treatment regimen, ie, no new specific anti-inflammatory treatment for sarcoidosis for at least 90 days, and stable dose(s) for at least 30 days prior to both the RHC qualifying for enrollment and randomization
  • 6-minute walk distance (6MWD) greater than or equal to (>=) 50 meters both at Screening and at the time of randomization. Participants can use their usual walking aids during the test (example, cane, crutches). The same walking aid should be used for all 6-minute walk test (6MWTs). Walkers are not allowed
  • Forced Vital Capacity (FVC) greater than (>) 50 percent (%) and Forced Expiratory Volume (in 1 second) () > 50% of predicted at Screening
  • Diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted. If DLCO less than (\<) 40% of predicted, the extent of emphysema should not be greater than that of fibrosis as assessed by high resolution computerized tomography (CT) scan
  • Women of must have a negative pregnancy test at screening and randomization, must agree to undertake monthly urine pregnancy tests, and to practice an acceptable method of and agreeing to remain on an acceptable method while receiving study intervention and until 30 days after last dose of study intervention
  • A woman only using hormonal contraceptives must have been using this method for at least 30 days prior to randomization

Main Exclusion Criteria:

  • PH due to left heart disease (PAWP >15 mmHg).
  • History of left heart failure (LHF) as assessed by the investigator including cardiomyopathies, and cardiac sarcoidosis, with a (LVEF) \<40%.
  • Treatment with prostacyclin, prostacyclin analogues or IP receptor agonists (ie, selexipag) within 90 days prior to randomization and/or prior to the RHC qualifying for enrollment, except those given at vasodilator testing during RHC.
  • SBP \<90 mmHg at Screening or at randomization.
  • Included on a lung transplant list or planned to be included until Visit 6 / Week 39.
  • Change in dose or initiation of new diuretics and/or calcium channel blockers within 1 week prior to RHC qualifying for enrollment.
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interests of the participant (eg, compromise well-being), or that could prevent, limit, or confound the protocol-specified assessments.
  • Any acute or chronic impairment that may influence the ability to comply with study requirements such as to perform RHC, a reliable and reproducible 6MWT, or lung function tests.
  • Any other criteria as per selexipag Summary of Product Characteristics (SmPC)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Selexipag 200 micro gram (μg)

    Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) twice daily/once daily. Dosing frequency will be twice daily, except for participants with moderate hepatic impairment (Child-Pugh Class B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention once daily. The dose will be up-titrated by the investigator/delegate in 200 μg twice daily/once daily increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg twice daily/once daily.

    Drug: Selexipag

  • Placebo comparator
    Placebo

    The comparator will be administered similarly to the experimental intervention.

    Drug: Placebo

Interventions

  • Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration

    Also known as: JNJ-678896049; ACT-293987

  • DrugPlacebo

    Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.

06

What researchers measure

Primary outcomes

  1. Pulmonary Vascular Resistance (PVR) up to Week 26

    PVR represents the resistance against which the right ventricle needs to pump. PVR was determined by right heart catheterization (RHC). It was measured as the ratio of the PVR value post-treatment initiation up to Week 26 (post) versus the PVR value pre-treatment initiation at baseline (pre), expressed as a percentage of baseline value. The baseline reference value for PVR was based on the last RHC performed prior to study intervention initiation. PVR was calculated as 80\*(mean pulmonary arterial pressure - pulmonary artery wedge pressure) divided by cardiac output. As specified in the statistical analysis plan, data was not planned to be summarized for this outcome measure and only individual participant wise data was collected.

    Time frame: Baseline up to Week 26

07

Results

Posted May 8, 2024
Limitations and caveats
All planned efficacy analyses could not be performed due to early termination of study.

Participant flow

Participant flow — Overall Study
MilestoneSelexipag 200 Micrograms (mcg)Placebo
Started64
Completed00
Not completed64
Withdrew: Death10
Withdrew: Study terminated by sponsor53
Withdrew: Adverse event01

Outcome measures

PrimaryPulmonary Vascular Resistance (PVR) up to Week 26

PVR represents the resistance against which the right ventricle needs to pump. PVR was determined by right heart catheterization (RHC). It was measured as the ratio of the PVR value post-treatment initiation up to Week 26 (post) versus the PVR value pre-treatment initiation at baseline (pre), expressed as a percentage of baseline value. The baseline reference value for PVR was based on the last RHC performed prior to study intervention initiation. PVR was calculated as 80\*(mean pulmonary arterial pressure - pulmonary artery wedge pressure) divided by cardiac output. As specified in the statistical analysis plan, data was not planned to be summarized for this outcome measure and only individual participant wise data was collected.

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of baseline PVR
Pulmonary Vascular Resistance (PVR) up to Week 26
percentage of baseline PVRSelexipag 200 Micrograms (mcg)Placebo
Participant 1—89.0
Participant 2—201
Participant 3—56
Participant 488—
Participant 5100—
Participant 647.0—
Participant 782.0—
Participant 886.0—

Adverse events

Collected over From Day 1 up to 456 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag 200 Micrograms (mcg)1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Placebo0/4 (0%)3/4 (75%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventSelexipag 200 Micrograms (mcg)Placebo
Angina PectorisCardiac disorders0/61/4
Pneumonia AspirationInfections and infestations0/61/4
DyspnoeaRespiratory, thoracic and mediastinal disorders0/61/4
Pulmonary HypertensionRespiratory, thoracic and mediastinal disorders0/61/4
Cardiac FailureCardiac disorders1/60/4
PneumoniaInfections and infestations1/60/4
Urinary Tract InfectionInfections and infestations1/60/4
FallInjury, poisoning and procedural complications1/60/4
Most frequent other events
Showing 10 of 47
Most frequent other events
EventSelexipag 200 Micrograms (mcg)Placebo
HeadacheNervous system disorders5/61/4
DiarrhoeaGastrointestinal disorders4/61/4
ArthralgiaMusculoskeletal and connective tissue disorders4/60/4
Pain in ExtremityMusculoskeletal and connective tissue disorders4/60/4
Covid-19Infections and infestations3/60/4
Pain in JawMusculoskeletal and connective tissue disorders3/60/4
NauseaGastrointestinal disorders2/60/4
MigraineNervous system disorders2/60/4
MalaiseGeneral disorders0/61/4
Lower Respiratory Tract InfectionInfections and infestations0/61/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Selexipag 200 Micrograms (mcg)PlaceboTotal
<=18 years000
Between 18 and 65 years404
>=65 years246
Age, Continuous
Age, Continuous(years)Selexipag 200 Micrograms (mcg)PlaceboTotal
Mean55 ± 14.5368.5 ± 2.3860.4 ± 12.95
Sex: Female, Male
Sex: Female, Male(Participants)Selexipag 200 Micrograms (mcg)PlaceboTotal
Female224
Male426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selexipag 200 Micrograms (mcg)PlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino538
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selexipag 200 Micrograms (mcg)PlaceboTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White538
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Selexipag 200 Micrograms (mcg)PlaceboTotal
France011
Germany404
Spain112
United Kingdom101
United States022
08

Study locations

38 sites
  • St. Vincent Medical Group, Inc.
    Indianapolis, Indiana 46260, United States
  • LSU Health Sciences Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195-0001, United States
  • Medical University of South Carolina (MUSC) - College of Medicine (COM)
    Charleston, South Carolina 29425-8900, United States
  • Universitaire Ziekenhuizen Leuven
    Leuven, 3000, Belgium
  • Secretaria da Saude do Estado do Ceara - Hospital Doutor Carlos Alberto Studart Gomes
    Fortaleza, 60840-285, Brazil
  • Hospital das Clinicas de Porto Alegre
    Porto Alegre, 90035-903, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    Sao Paulo, 05403-000, Brazil
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Hôpital Avicenne
    Bobigny, 93000, France
  • GH est - Hôpital Cardiovasculaire et Pneumologie Louis Pradel
    Bron Cedex, 69677, France
  • Hôpital Kremlin Bicêtre
    Le Kremlin Bicetre Cedex, 94270, France
  • Hopital Nord
    Marseille cedex 20, 13915, France
  • CHU de Nancy - Hopital de Brabois
    Vandoeuvre les Nancy Cedex, 54511, France
  • Evangelische Lungenklinik Berlin
    Berlin, 13125, Germany
  • Universitatsklinikum Bonn
    Bonn, 53105, Germany
  • Universitatsklinikum Carl Gustav Carcus Dresden
    Dresden, 01307, Germany
  • Thoraxklinik Heidelberg
    Heidelberg, 69126, Germany
  • Universitatsklinikum Schleswig Holstein
    Luebeck, 23538, Germany
  • Universitaetsklinikum Regensburg
    Regensburg, 93053, Germany
  • RBK Lungenzentrum Stuttgart am Robert-Bosch-Krankenhaus
    Stuttgart, 70839, Germany
  • Klinikum Würzburg Mitte gGmbH Standort Missioklinik
    Würzburg, 97074, Germany
  • Ospedale S.Giuseppe, Gruppo MultiMedica
    Milano, 20123, Italy
  • Fondazione Maugeri Montescano
    Pavia, 27100, Italy
  • Umberto I Pol. di Roma-Università di Roma La Sapienza
    Roma, 00165, Italy
  • Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli'
    Roma, 00168, Italy
  • A.O.U. Città della Salute e della Scienza
    Torino, 10126, Italy
  • VUMC Amsterdam
    Amsterdam, 1081 HV, Netherlands
  • Sint Antonius Ziekenhuis
    Nieuwegein, 3435 CM, Netherlands
  • Hosp. Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hosp. Univ. Marques de Valdecilla
    Santander, 39008, Spain
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Actelion is a Janssen pharmaceutical company of Johnson \& Johnson. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Apr 2023, 25 months.

Results were first posted in May 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2019
First posted
May 8, 2019
StartActual
Feb 26, 2021
Primary completionActual
Apr 19, 2023
CompletionActual
Apr 19, 2023
Results first posted
May 8, 2024
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03942211
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Feb 26, 2021
Primary completion
Apr 19, 2023
Completion
Apr 19, 2023
Results posted
May 8, 2024
Last update
May 8, 2024

Study contacts

Rainer Zimmermann
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion